These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond

Obesity drugs are arguably the hottest growth opportunity in the healthcare sector.These drugs primarily work by slowing digestion and suppressing patients' appetites. What began as a treatment for type 2 diabetes has expanded into the broader weight management space, creating a surging market opportunity. According to Morgan Stanley, obesity drug sales could grow from $15 billion last year to $150 billion by 2035.Two pharmaceutical companies have dominated the industry with their current-generation subcutaneous (injected) drugs, but the stakes are high as next-generation treatments near regulatory approval, including oral (pill) formulations.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool